Revelation Biosciences In...

2.57
-0.13 (-4.81%)
At close: Mar 31, 2025, 12:40 PM
-4.81%
Bid 2.57
Market Cap 2.33M
Revenue (ttm) 14.23K
Net Income (ttm) -7.94B
EPS (ttm) -87.68
PE Ratio (ttm) -0.03
Forward PE -0.13
Analyst n/a
Ask 2.81
Volume 10,408
Avg. Volume (20D) 246,745
Open 2.66
Previous Close 2.70
Day's Range 2.51 - 2.80
52-Week Range 2.36 - 60.80
Beta 0.18

About REVB

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is a...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2020
Employees 8
Stock Exchange NASDAQ
Ticker Symbol REVB
Full Company Profile
2 months ago
-23.84%
Revelation Biosciences shares are trading lower af... Unlock content with Pro Subscription
3 months ago
+25%
Revelation Biosciences shares are trading higher after the company announced FDA acceptance of Gemini IND.